To promote turnkey solution for plasma-derived therapeutics
ProMetic Life Sciences has expanded its collaboration with Sartorius Stedim Biotech (SSB) to include a contribution of equipment to ProMetic's plasma purification facility. It has also agreed the co-commercialisation of Plasma Protein Purification System (PPPS) on a global basis.
SSB will provide filtration equipment and other consumables for ProMetic's plasma purification plant, which is set to be operational in the fourth quarter. ProMetic says SSB's contribution represents a significant investment over the next 3 years as plasma-derived products manufactured in the GMP facility undergo regulatory approval. No further financial details have been revealed.
The agreement also confirms SSB as a preferred supplier of filtration equipment and consumables for ProMetic's PPPS licensees. SSB filtration equipment and consumables will be offered as an integral part of ProMetic's offering of plasma purification turnkey processes.
The successful scale-up of the PPPS technology represents a unique opportunity to provide the plasma purification industry with a novel turnkey process
Dr Uwe Gottschalk, Vice-President of Marketing for Purification Technologies at SSB said: ‘The successful scale-up of the PPPS technology represents a unique opportunity to provide the plasma purification industry with a novel turnkey process, which achieves significantly improved yields and purity, while using a smaller plant footprint compared with current industry practices. We are happy to contribute our globally recognised engineering and technical expertise to our expanded partnership. We believe this will facilitate and accelerate market penetration.’
ProMetic and SSB have also agreed to expand their co-commercialisation efforts of the PPPS technology to include respective technological and engineering solution transfers with the aim of accelerating penetration of Asia and other emerging markets.
ProMetic's plasma purification facility created for the development and manufacturing of high-value plasma-derived therapeutics will become a technological showroom for the PPPS technology.